Authors' recommendations: Type 2 diabetes is a disease that results in the levels of sugar in the blood being too high. This can cause damage to the eyes, nerves, kidneys and other tissues, and can greatly increase the chances of heart attacks and strokes, especially when combined with high blood pressure and high blood cholesterol levels. Empagliflozin is a drug currently used to treat type 2 diabetes. It is given as a tablet that is taken once daily. In a large study of patients, empagliflozin reduced the risk of getting high blood pressure, heart attacks and strokes in people with type 2 diabetes. If licensed in the UK, empagliflozin will offer type 2 diabetes patients who are at risk of developing heart disease and strokes, an additional treatment option which can be used with other diabetes drugs.

Project Status: Completed

Year Published: 2016

URL for published report: http://www.hsric.nihr.ac.uk/topics/empagliflozin-jardiance-for-preventing-cardiovascular-death-in-patients-with-type-2-diabetes-mellitus-and-high-cardiovascular-risk/

English language abstract: An English language summary is available

Publication Type: Not Assigned

Country: England, United Kingdom

Organisation Name: NIHR Horizon Scanning Centre

Contact Address: The NIHR Horizon Scanning Centre, Department of Public Health, Epidemiology, and Biostatistics, School of Health and Population Sciences, University of Birmingham, 90 Vincent Drive, Edgbaston, Birmingham, B15 2SP. United Kingdom. Tel: +44 121 414 7831, Fax: +44 121 2269

Contact Name: c.packer@bham.ac.uk

Contact Email: c.packer@bham.ac.uk

Copyright: NIHR Horizon Scanning Research&Intelligence Centre (NIHR HSRIC)